title: Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment.
abstract: BACKGROUND
  The usefulness of celiac disease-related serology in monitoring patients on a gluten-free diet has been debated.
  
  
  OBJECTIVE
  To describe serologic changes over time and assess whether serology tests can predict compliance with the gluten-free diet.
  
  
  METHODS
  Sera obtained at baseline and every 3 months thereafter for 1 year in 82 adult celiac disease patients were assayed for: (1) IgA antigliadin, (2) IgA anti-tissue transglutaminase, (3) IgA endomysial, (4) IgA, and (5) IgG anti-deamidated gliadin peptides, (6) dual detection of IgA and IgG anti-deamidated gliadin peptides, (7) a single assay for IgA and IgG of both anti-deamidated gliadin peptide and anti-tissue transglutaminase, and (8) IgA antiactin antibodies.
  
  
  RESULTS
  At 3 months after diagnosis, most antibody assays significant decrease in mean concentrations (p<0.0001) and the percentage of positive samples (p<0.0001) with further improvement in subsequent determinations. Strictly adherents had significantly lower concentrations of antibodies (p<0.01 to p<0.00001) and smaller proportion of positive samples for IgA endomysial, IgA antiactin antibodies and IgA antigliadin (15.6%, 17.4% and 23.9%, respectively) than partially compliant. At 1 year, IgA endomysial (p<0.02), IgA antiactin antibodies (p<0.05) and anti-tissue transglutaminase (p<0.02) predicted the degree of compliance.
  
  
  CONCLUSIONS
  Gluten-free diet treatment produced rapid and significant qualitative and quantitative changes in celiac disease-related antibodies which may be useful for monitoring dietary compliance.
authors.affiliation: Small Bowel Section, Department of Medicine, Dr. C. Bonorino Udaondo Gastroenterology Hospital, Buenos Aires, Argentina.
authors.forename: Emilia
authors.initials: E
authors.lastname: Sugai
authors.forename: Fabio
authors.initials: F
authors.lastname: Nachman
authors.forename: Horacio
authors.initials: H
authors.lastname: Váquez
authors.forename: Andrea
authors.initials: A
authors.lastname: González
authors.forename: Paola
authors.initials: P
authors.lastname: Andrenacci
authors.forename: Andrea
authors.initials: A
authors.lastname: Czech
authors.forename: Sonia
authors.initials: S
authors.lastname: Niveloni
authors.forename: Roberto
authors.initials: R
authors.lastname: Mazure
authors.forename: Edgardo
authors.initials: E
authors.lastname: Smecuol
authors.forename: Ana
authors.initials: A
authors.lastname: Cabanne
authors.forename: Eduardo
authors.initials: E
authors.lastname: Mauriño
authors.forename: Julio Cesar
authors.initials: JC
authors.lastname: Bai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood*; D002446:Celiac Disease / Q000178:diet therapy* / Q000276:immunology*; D055050:Diet, Gluten-Free; D005260:Female; D005903:Gliadin / Q000276:immunology; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011446:Prospective Studies; D011503:Transglutaminases / Q000276:immunology; D055815:Young Adult
chemical_list: D000906:Antibodies; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D005903:Gliadin; D011503:Transglutaminases